GeBra-clin
Étude Clinique Des Biomarqueurs de la résilience au Stress: rôle d'ELK1 et GPR56
Sponsor study identifier
Secondary identifiers
OTHER · 2022-A00070-43
interventional
255
1 country
4
Study Start
September 1, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
70% of Europeans will be exposed to a potentially traumatic event (PTE). Following this experience, people are likely to develop various psychiatric disorders such as post-traumatic stress disorder (PTSD) or a major depressive episode (MDE). However, not all subjects have the same risk to develop a pathology, and resilience capacities, which depend on multiple factors are difficult to predict. Currently, there are no objective tools to stratify exposed subjects according to their risk of developing pathological responses to stress, which leads to difficulties in allocating means of prevention and treatment. Recently, new biological hypotheses explaining vulnerability/resilience to stress and depression, implicating the GPR56 and ELK1 genes, have been described. Previous studies have shown that evaluation of the vulnerability risk can be obtained from clinical, cognitive, biological or brain imaging variables, but no study has integrated these different approaches. Therefore, the project presented here aims at integrating behavioral, biological and neuroimaging data to predict the development of psychiatric disease. In this study, a prospective cohort of 255 violent trauma victims will be set up in 3 French cities for a period of 2 years. Eligible subjects will be included in the month following PTE and will be followed longitudinally for 12 months. Evaluations at 1, 3, 6 and 12 months will be performed, during which the subject will complete various clinical and cognitive tests. A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood. For eligible subjects a brain MRI will be proposed at the first visit. We hypothesize that the genetic expression of ELK1 and GPR56 is predictive of the development of psychiatric pathologies at 6 and 12 months post-PTE. The ambition of this project is also to highlight the importance of a multimodal approach integrating a triad of markers (behavioral, biological and neuroimaging) to test this hypothesis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 3, 2022
Actual (reported)August 4, 2022
Actual (reported)September 1, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Predictive value of ELK1 and GPR56 mRNA levels separately and in combination for the development of psychiatric symptoms following PTE at 6-month follow-up.
6 months
Predictive value of the resilience prognosis of a transcriptomic and epigenetic signature (non-coding RNAs and DNA methylation) including GPR56 and ELK1 non-exclusively for the appearance of psychiatric symptoms following a PTE
12 months
Predictive value of structural MRI for the development of psychiatric symptoms following PTE
12 months
Predictive value of measure of cognitive functioning for the development of psychiatric symptoms following PTE
12 months
Predictive value of transcriptomic and epigenetic signature for the development of psychiatric symptoms following PTE
12 months
Predictive value of ELISA measurement of GPR56 and ELK1 in serum for the development of psychiatric symptoms following PTE
12 months
Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests. A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood. For eligible subjects a brain MRI will be proposed at the first visit.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Hopital de la Conception
Marseille, France
Hopital Sainte Marguerite
Marseille, France
CHU Montpellier
Montpellier, France
CHRU de Tours
Tours, France
François CREMIEUX
Assistance Publique Hopitaux De Marseille
First Submitted
August 3, 2022
First Posted
August 4, 2022
Study Start
September 1, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 31, 2025
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 5, 2022
Record last verified: 2022-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: